As a new atypical antipsychotic, brexpiprazole is primarily metabolized by cytochrome P450
3A4 (CYP3A4). However, genetic polymorphisms in CYP3A4 cause wide variability in …

Accurate prediction of CYP2D6 phenotype from genotype information is important to support
safe and efficacious pharmacotherapy with CYP2D6 substrates. To facilitate accurate …

Brexpiprazole is an oral antipsychotic agent indicated for use in patients with schizophrenia,
or as adjunctive treatment for major depressive disorder. As cytochrome P450 (CYP) 2D6 …

Rationale Brexpiprazole is a novel serotonin–dopamine activity modulator approved by the
USFDA in July 2015 for the treatment of schizophrenia and as an adjunctive therapy with …

Aims Rabeprazole is known to be a substrate of CYP2C19. Our objective was to evaluate
the possible effect of an inhibitor of CYP2C19, fluvoxamine, and compare the inhibitory …

Objective Rabeprazole as a proton pump inhibitor (PPI) is mainly reduced to rabeprazole
thioether via a nonenzymatic pathway, with minor CYP2C19 and CYP3A4 involvement. The …

Brexpiprazole (BRX) is approved for the treatment of schizophrenia and major depressive
disorders and it is mainly metabolized by CYP3A4 and CYP2D6. Grapefruit juice (GFJ) …

Background: S‐mephenytoin 4'‐hydroxylase (CYP2C19) catalyses the metabolism of
rabeprazole to some extent. Based on the metabolic and pharmacokinetic differences …

Alprazolam is a triazolobenzodiazepine which is most commonly used in the short-term
management of anxiety disorders, often in combination with antipsychotics. The four human …

Aim Rabeprazole is metabolized to some extent by CYP2C19. The purpose of this study was
to elucidate the pharmacokinetics of each rabeprazole enantiomer in three different …